Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Munch-a-Biotech Today -- Ignore unavailable to you. Want to Upgrade?

To: tuck who wrote (2920)	12/2/2010 3:13:54 PM
From: keokalani'nui	Respond to of 3158

SmartCells attaches insulin to a biodegradable polymer which holds the insulin in place and via competitive binding releases the polymer into the bloodstream when BG rises. Would have enormous potential. Good that some big money is behind it now. Merck & Co., the second-biggest U.S. drug company, agreed to pay as much as $500 million for closely held SmartCells Inc., maker of an experimental diabetes treatment designed to better regulate insulin in the blood. SmartCells will receive upfront cash plus additional payments if products developed from the treatment meet clinical and regulatory goals, Whitehouse Station, New Jersey-based Merck said in a statement today. Investors in Beverly, Massachusetts-based SmartCells may get more money depending on future sales, according to the statement.